MGC Pharma granted approval in Slovenia to manufacture and conduct research into psychedelics

49w
2m read
Summary

The approval in Slovenia will allow MGC Pharma to become one of the first movers in the burgeoning space of psychedelics. This article was developed in collaboration with MGC Pharma, a Stockhead advertiser at the time of publishing. MGC Pharma (ASX:MXC) is set to  expand its European footprints further after receiving permission from the Slovenian Ministry of Health to undergo scientific research on the psychedelic compound, psilocybin. MGC Pharma has a rapidly expanding pipeline. The permission allows MGC to develop analytical methods, research physical-chemical properties of psilocybin, and undergo the development of pharmaceutical forms that would be suitable for administration in Slovenia.

Article Preview

Stockhead..

 

The approval in Slovenia will allow MGC Pharma to become one of the first movers in the burgeoning space of psychedelics.

MGC Pharma (ASX:MXC) is set to  expand its European footprints further after receiving permission from the Slovenian Ministry of Health to undergo scientific research on the psychedelic compound, psilocybin.

The permission allows MGC to develop analytical methods, research physical-chemical properties of psilocybin, and undergo the development of pharmaceutical forms that...

Read the full article @ Cannabis Law Report